Amidst the COVID-19 pandemic, there has been an evident surge in the demand for high quality cell therapies intended for research and therapeutic purposes, ..
Amidst the COVID-19 pandemic, there has been an evident surge in the demand for high quality cell therapies intended for research and therapeutic purposes, ..
Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated ..
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical ..